DK0625053T3 - Urease-baseret vaccine mod Helicobacter-infektion - Google Patents

Urease-baseret vaccine mod Helicobacter-infektion

Info

Publication number
DK0625053T3
DK0625053T3 DK94900794T DK94900794T DK0625053T3 DK 0625053 T3 DK0625053 T3 DK 0625053T3 DK 94900794 T DK94900794 T DK 94900794T DK 94900794 T DK94900794 T DK 94900794T DK 0625053 T3 DK0625053 T3 DK 0625053T3
Authority
DK
Denmark
Prior art keywords
urease
vaccine against
based vaccine
helicobacter infection
against helicobacter
Prior art date
Application number
DK94900794T
Other languages
Danish (da)
English (en)
Inventor
Pierre Michetti
Andre Blum
Catherine Davin
Rainer Max Planck Institu Haas
Irene Corthesy-Theulaz
Jean-Pierre Kraehenbuhl
Emilia Saraga
Original Assignee
Oravax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25517797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0625053(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oravax Inc filed Critical Oravax Inc
Application granted granted Critical
Publication of DK0625053T3 publication Critical patent/DK0625053T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
DK94900794T 1992-11-03 1993-11-02 Urease-baseret vaccine mod Helicobacter-infektion DK0625053T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97099692A 1992-11-03 1992-11-03
US08/085,938 US5972336A (en) 1992-11-03 1993-07-06 Urease-based vaccine against helicobacter infection
PCT/EP1993/003059 WO1994009823A1 (fr) 1992-11-03 1993-11-02 Vaccin a base d'urease contre l'infection due a l'helicobacter

Publications (1)

Publication Number Publication Date
DK0625053T3 true DK0625053T3 (da) 2002-08-12

Family

ID=25517797

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94900794T DK0625053T3 (da) 1992-11-03 1993-11-02 Urease-baseret vaccine mod Helicobacter-infektion

Country Status (29)

Country Link
US (1) US5972336A (fr)
EP (2) EP1170016A3 (fr)
JP (1) JPH07503255A (fr)
KR (1) KR100287424B1 (fr)
CN (1) CN1111429C (fr)
AT (1) ATE217196T1 (fr)
AU (2) AU678195C (fr)
BR (1) BR9305711A (fr)
CA (1) CA2127283A1 (fr)
CZ (1) CZ284416B6 (fr)
DE (1) DE69331901T2 (fr)
DK (1) DK0625053T3 (fr)
ES (1) ES2176232T3 (fr)
FI (1) FI112032B (fr)
GE (1) GEP20012429B (fr)
HU (1) HU219760B (fr)
IL (1) IL107474A (fr)
MX (1) MX9306841A (fr)
NO (1) NO942490L (fr)
NZ (2) NZ299149A (fr)
OA (1) OA10087A (fr)
PL (1) PL174448B1 (fr)
PT (1) PT625053E (fr)
RO (1) RO114870B1 (fr)
RU (1) RU2125891C1 (fr)
SG (1) SG70978A1 (fr)
SK (1) SK280619B6 (fr)
WO (1) WO1994009823A1 (fr)
ZA (1) ZA938203B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
US6258359B1 (en) * 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
WO1995014093A1 (fr) 1993-05-19 1995-05-26 Institut Pasteur Compositions immunogenes dirigees contre les infections par helicobacter, polypeptides utilisables dans ces compositions, et sequences d'acides nucleiques codant ces polypeptides
ATE244578T1 (de) * 1993-07-27 2003-07-15 Csl Ltd Behandlung eines durch helicobakter verursachten gastroduodenalen krankheit
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
AU702878B2 (en) * 1994-06-08 1999-03-11 Csl Limited Treatment and prevention of helicobacter infection
AUPM612494A0 (en) 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
GB2303855B (en) * 1994-07-01 1998-10-28 Rican Limited Helicobacter pylori antigenic protein preparation and immunoassays
WO1996033732A1 (fr) * 1995-04-28 1996-10-31 Oravax, Inc. Vaccin d'urease recombinante et multimere
US5837240A (en) * 1995-04-28 1998-11-17 Oravax-Merieux Co. Multimeric, recombinant urease vaccine
JPH11510164A (ja) * 1995-07-26 1999-09-07 マキシム ファーマシューティカルズ ポリヌクレオチドの粘膜送達
GB2307987A (en) * 1995-12-06 1997-06-11 Univ Manchester Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto
US6248551B1 (en) * 1997-03-28 2001-06-19 Institut Pasteur Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides
US20020026035A1 (en) * 1997-04-01 2002-02-28 Harold Kleanthous Helicobacter ghpo 1360 and ghpo 750 polypeptides and corresponding polynucleotide molecules
AU7537598A (en) * 1997-04-30 1998-11-24 Pasteur Merieux Serums Et Vaccins Dna based anti-(helicobacter) vaccine composition
US20030158396A1 (en) * 1997-07-29 2003-08-21 Harold Kleanthous Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
US5985631A (en) * 1997-09-12 1999-11-16 Oravax-Merieux Co. Method for preventing the activation of inactive, recombinant Helicobacter pylori apourease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20020151462A1 (en) * 1998-02-19 2002-10-17 Ling Lissolo Helicobacter pylori membrane proteins
GB9807721D0 (en) * 1998-04-08 1998-06-10 Chiron Spa Antigen
US6576244B1 (en) 1998-06-19 2003-06-10 Acambis, Inc. LT and CT in parenteral immunization methods against helicobacter infection
US6190667B1 (en) 1998-06-30 2001-02-20 Institut Pasteur Methods of inhibiting Helicobacter pylori
WO2000003730A1 (fr) * 1998-07-16 2000-01-27 Cheil Jedang Corporation VACCIN A BASE D'UREASE CONTRE LES INFECTIONS A $i(HELICOBACTER)
CA2361377C (fr) * 1999-02-05 2009-02-03 Alk-Abello A/S Nouveau systeme d'administration par les muqueuses
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
US20020107368A1 (en) * 2000-12-07 2002-08-08 Jing-Hui Tian Helicobacter proteins, gene sequences and uses thereof
AUPR524101A0 (en) * 2001-05-25 2001-06-21 Council Of The Queensland Institute Of Medical Research, The Antigen targeting
AU2002346249B2 (en) * 2001-06-07 2007-03-15 The Regents Of The University Of Colorado Mutant Forms of Cholera Holotoxin as an Adjuvant
IL159209A0 (en) * 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2006066089A1 (fr) 2004-12-15 2006-06-22 Neuralab Limited Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN100460014C (zh) * 2006-07-20 2009-02-11 中国人民解放军第三军医大学 基于尿素酶b亚单位活性片段的幽门螺杆菌疫苗及其制备方法
KR20090083927A (ko) * 2006-11-10 2009-08-04 배리 제이. 마샬 펩타이드를 위 점막에 전달하기 위한 방법 및 장치
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
KR100982489B1 (ko) * 2007-12-17 2010-09-15 대구한의대학교산학협력단 헬리코박터 파일로리로부터 유래된 항원을 이용하여헬리코박터 파일로리 특이 항체 생산을 위한 백신을제조하는 방법
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
PL218700B1 (pl) 2012-03-29 2015-01-30 Gdański Univ Medyczny Doustna szczepionka zawierająca przetrwalniki Bacillus subtilis oraz jej zastosowanie do immunizacji przeciwko Helicobacter pylori
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
EP2837939A1 (fr) * 2013-08-13 2015-02-18 Technische Universität München Procédé pour la détection de l'infection par H.pylori
EP3539564A1 (fr) 2013-11-04 2019-09-18 UTI Limited Partnership Méthodes et compositions d'immunothérapie soutenue
BR112017023853A2 (pt) 2015-05-06 2018-07-17 Uti Limited Partnership composições de nanopartícula para terapia sustentada.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5268276A (en) * 1988-09-16 1993-12-07 Jan Holmgren Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
FR2637612B1 (fr) * 1988-10-06 1993-09-10 Pasteur Institut Sequences de nucleotides codant pour une proteine a activite ureasique
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
JPH04169539A (ja) * 1990-11-01 1992-06-17 Imuno Japan:Kk 消化器疾患治療・予防剤およびその製造方法
JPH06507494A (ja) * 1991-04-26 1994-08-25 カレノフ,エマニユエル 細菌性アレルゲンにより惹起される疾患の検出及び治療方法
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
US5859219A (en) * 1992-02-26 1999-01-12 Vanderbilt University Purified vacuolating toxin from Helicobacter pylori and methods to use same
EP0967279B1 (fr) * 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Cytotoxine d' Helicobacter pylori utile dans des vaccins et en diagnostique
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
US5733740A (en) * 1992-10-13 1998-03-31 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
US6258359B1 (en) * 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
US5681736A (en) * 1994-10-05 1997-10-28 Antex Biologics, Inc. Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same
US5837240A (en) * 1995-04-28 1998-11-17 Oravax-Merieux Co. Multimeric, recombinant urease vaccine

Also Published As

Publication number Publication date
CZ160994A3 (en) 1995-04-12
FI943171A (fi) 1994-09-01
SK280619B6 (sk) 2000-05-16
JPH07503255A (ja) 1995-04-06
CN1094640A (zh) 1994-11-09
GEP20012429B (en) 2001-05-25
NO942490L (no) 1994-08-22
MX9306841A (es) 1995-01-31
SK79394A3 (en) 1996-09-04
AU678195C (en) 2003-06-12
AU2003270987A1 (en) 2004-01-22
KR100287424B1 (ko) 2001-04-16
PL304419A1 (en) 1995-01-09
NO942490D0 (no) 1994-07-01
EP1170016A2 (fr) 2002-01-09
IL107474A (en) 1998-09-24
PL174448B1 (pl) 1998-07-31
AU5561994A (en) 1994-05-24
RU2125891C1 (ru) 1999-02-10
DE69331901T2 (de) 2002-10-31
NZ299149A (en) 1997-12-19
HU219760B (hu) 2001-07-30
ZA938203B (en) 1994-06-09
HUT69938A (en) 1995-09-28
HU9402261D0 (en) 1994-10-28
CZ284416B6 (cs) 1998-11-11
AU678195B2 (en) 1997-05-22
EP1170016A3 (fr) 2002-03-06
FI943171A0 (fi) 1994-07-01
CN1111429C (zh) 2003-06-18
DE69331901D1 (de) 2002-06-13
ATE217196T1 (de) 2002-05-15
PT625053E (pt) 2002-09-30
EP0625053A1 (fr) 1994-11-23
SG70978A1 (en) 2000-03-21
WO1994009823A1 (fr) 1994-05-11
BR9305711A (pt) 1997-02-18
RO114870B1 (ro) 1999-08-30
IL107474A0 (en) 1994-02-27
NZ258118A (en) 1997-04-24
CA2127283A1 (fr) 1994-05-11
ES2176232T3 (es) 2002-12-01
US5972336A (en) 1999-10-26
EP0625053B1 (fr) 2002-05-08
FI112032B (fi) 2003-10-31
OA10087A (en) 1996-12-18

Similar Documents

Publication Publication Date Title
DK0625053T3 (da) Urease-baseret vaccine mod Helicobacter-infektion
NO963508L (no) Urease-basert vaksine og behandling av Helicobacter-infeksjon
ES2092306T3 (es) Adyuvante para vacunas.
MX9301706A (es) Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
RU93058676A (ru) Оральное лечение геликобактерной инфекции
SE7613851L (sv) Glukosaminderivat
FI851859L (fi) Antigenpreparat och isolering av saodana preparat.
LU91595I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine et de polyoside capsulaire d'haemophilus influenzae type b (InfanrixHib)
NZ314585A (en) Method of treating H. Pylori associated gastroduodenal disease
NO924271D0 (no) Vaksiner med forbedret immunogenisitet
SE9604322D0 (sv) Bacterial antigens and vaccine compositions II
ATE329615T1 (de) Borrelia burgdorferi bacterin
FR2646776B1 (fr) Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
DK52783A (da) Vaccine indeholdende en ozon-inaktiveret mikroorganisme og fremgangsmaade til fremstilling af en saadan vaccine
ES515472A0 (es) Procedimiento para proteger anfitriones susceptibles de infeccion de hepatitis.
ATE110964T1 (de) Pertussistoxoid-impfstoff.
NO934547L (no) Oral behandling av Helicobacter-infeksjon
MX9604262A (es) Antigenos de pasteurellaceae y vacunas relacionadas.